Paliperidon, a Second - generation Antipsychotic: Efficacy, Tolarability, and Drug-Drug Interactions
Abstract
Paliperidone is a pharmacologically active metabolite of risperidone. Now it will be possible to use paliperidone in advanced delivery system ORoS with osmetic controlled release for 24hodin.
Paliperidone was tested in four 6-week double-blind studies involving 1 804 patients with schizophrenic disorder. The range of daily doses being 3-15 mg, paliperidone was more efficient than placebo and comparably efficient to olanzapine.
It was successful in influencing a whole range of schizophrenic psychopathology. i. e. positive, negative and affective symptoms, hostility excitation, thought disorganization and insomnia. Onset of the effect was observed as early as after 4 days of therapy.
In a long-term double blind trial paliperidone prevented relapses of schizophrenia more successfully than placbo. Paliperidone is administered once daily without need for dose titration.
As for side effects, extrapyramidal symptoms were most frequent, hypotension and somnolence occurred rarely. Although paliperidone elevated prolactinemia, corresponding clinical symptoms were observed only in 2-4 % of patients.
The new antipsychotic drug did not affect serum lipids or glycaemia and body weight was affected only to a minimum extent. Paliperidone has very few drug - drug interactions.